Antibody-drug conjugates (ADCs): all 1,111 studies that test it
Page 11 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.
- Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03084939Phase 3
- A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT03070990Phase 1
- A Study of RC48-ADC in Subjects With Advanced Breast CancerCompletedNCT03052634Phase 1/2
- Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBCWithdrawnNCT03045393Phase 1
- Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT03013933Phase 1
- Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by SurgeryActive, not recruitingNCT03007030Phase 2
- Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast CancerCompletedNCT02996825Phase 1
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingNCT02981628Phase 2
- Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid TumorsCompletedNCT02881190Phase 1
- A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid TumorsCompletedNCT02881138Phase 1
- TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary SyndromeCompletedNCT02822586Phase 1
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell LymphomaWithdrawnNCT02729961Phase 1/2
- Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast CancerWithdrawnNCT02725541Phase 2
- International Randomised Phase III Clinical Trial in Children With Acute Myeloid LeukaemiaActive, not recruitingNCT02724163Phase 3
- Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICECompletedNCT02686346Phase 1/2
- Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersCompletedNCT02675829Phase 2
- HD21 for Advanced StagesActive, not recruitingNCT02661503Phase 3
- A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell LymphomaCompletedNCT02616965Phase 1
- Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
- A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.CompletedNCT02576548Phase 1
- Neoadjuvant Response-guided Treatment of HER2 Positive Breast CancerActive, not recruitingNCT02568839Phase 2/3
- A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidityCompletedNCT02567851Phase 2
- Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage SettingTerminatedNCT02499627Phase 2
- Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL PatientsCompletedNCT02497131Phase 2
- Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4CompletedNCT02473146Phase 2/3
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVDCompletedNCT02298283Phase 2
- Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.CompletedNCT02292979Phase 2
- Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma PatientsStatus unknownNCT02280993Phase 1
- Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin LymphomasCompletedNCT02280785Phase 2
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaTerminatedNCT02254239Phase 1
- BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEVCompletedNCT02244021Phase 2
- Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02243436Phase 1/2
- Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.CompletedNCT02227433Phase 2
- Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSCompletedNCT02221310Phase 2
- Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin LymphomaCompletedNCT02191930Phase 2
- DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLCompletedNCT02182596Phase 1/2
- Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerWithdrawnNCT02161679Phase 2
- Patients With Brain Metastases From HER2-positive Breast CancerCompletedNCT02135159Phase 1
- SCT Plus Immune Therapy in Average Risk AML/MDSCompletedNCT02117297Phase 2
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingNCT02099058Phase 1
- A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4CompletedNCT02091999Phase 1
- Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02086604Phase 1
- T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast CancerCompletedNCT02073916Phase 1
- Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.CompletedNCT01975142Phase 2
- Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)TerminatedNCT01940796Phase 1
- Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01902160Phase 1
- Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaCompletedNCT01868451Not applicable
- Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell TumorsCompletedNCT01851200Phase 2
- Brentuximab Vedotin + Re-induction Chemotherapy for AMLCompletedNCT01830777Phase 1
- Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT01816035Phase 1
- A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.CompletedNCT01745965Phase 2
- Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
- Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of ElderlyWithdrawnNCT01671813Not applicable
- Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesWithdrawnNCT01620229Phase 1/2
- Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host DiseaseWithdrawnNCT01616680Phase 2
- Brentuximab Vedotin for Steroid Refractory GvHDCompletedNCT01596218Phase 1
- Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second RelapseCompletedNCT01562990Phase 1/2
- Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaWithdrawnNCT01548911Phase 2
- Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphomaCompletedNCT01535989Phase 1
- A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic FunctionCompletedNCT01513083Phase 1
- A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4CompletedNCT01409135Phase 1
- SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsCompletedNCT01309789Phase 1
- A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins LymphomaCompletedNCT01290549Phase 1
- A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin LymphomaCompletedNCT01060904Phase 1
- LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
- Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
- Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
- Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaCompletedNCT01020539Phase 1
- Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionCompletedNCT00962767Phase 3
- Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based TherapyCompletedNCT00928330Phase 1
- Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationCompletedNCT00893399Phase 3
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2
- Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT00717925Phase 1
- Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLTerminatedNCT00669890Phase 1
- Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid LeukemiaTerminatedNCT00660036Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT00577694Phase 1
- NOPHO-AML 2004 Study for Children With Acute Myeloid LeukemiaCompletedNCT00476541Phase 3
- Gemtuzumab Ozogamicin Before Allogeneic Stem Cell TransplantationStatus unknownNCT00460447Phase 1/2
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCompletedNCT00454480Phase 2/3
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
- Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With LeukemiaCompletedNCT00304447Phase 4
- A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid LeukemiaCompletedNCT00233909Phase 1/2
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)CompletedNCT00143975Phase 2
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaStatus unknownNCT00091234Phase 2/3
- Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00089050Phase 2
- Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
- Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification TherapyCompletedNCT00070174Phase 2
- Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00052299Phase 3
- S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00049179Phase 2